Haythem Ali, MD
Medical Oncology · Detroit, MINPI 1174691695
Payments from drug & device makers
Across 648 payments — averaging $8677.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.6M
- Seagen Inc.$1.5M
- Pfizer$1.4M
- AstraZeneca$624K
- Novartis$246K
- Genentech, Inc.$120K
- plus $250K from 16 others
Across 1 payment — averaging $1139.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 248 | $1,551,309 |
| Seagen Inc. | 164 | $1,462,574 |
| Pfizer | 59 | $1,369,729 |
| AstraZeneca | 44 | $623,781 |
| Novartis | 14 | $246,120 |
| Genentech, Inc. | 15 | $119,879 |
| Daiichi Sankyo Inc. | 52 | $103,829 |
| Astrazeneca UK Limited | 16 | $76,505 |
| Merck Healthcare Kgaa | 5 | $55,634 |
| Genentech USA, Inc. | 8 | $5,946 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,250 |
| Sanofi | 1 | $1,904 |
| Stemline Therapeutics Inc. | 2 | $1,608 |
| Eli Lilly | 2 | $500 |
| Gilead | 6 | $481 |
| E.r. Squibb & Sons, L.L.C. | 2 | $399 |
| Astellas Pharma US Inc | 2 | $195 |
| Athenex Pharmaceutical Division, LLC | 1 | $175 |
| Puma Biotechnology, Inc. | 3 | $142 |
| Lilly USA, LLC | 1 | $125 |
| Tempus AI, Inc | 1 | $80 |
| Exelixis Inc. | 1 | $19 |
How this compares
$5,623,184 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Detroit
- Patricia Lo RussoDetroit$24.6M
- Shirish GadgeelDetroit$11M
- Ammar SukariDetroit$8.4M
- Clara HwangDetroit$4.2M
- Dipesh UpretyDetroit$3.3M
- Amy WeiseDetroit$3M
- Bassel El-RayesDetroit$2.3M
- Ahmed KasebDetroit$1.5M
- Philip PhilipDetroit$1.3M
- Charles SchifferDetroit$617K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.